The company behind microRNA intelligence.
miRoncol brings scientific discovery, clinical judgment, AI-assisted analysis and diagnostic-development experience together around one goal: make meaningful biological change visible sooner and help protect more years of healthy life.
Understand the company from three perspectives.
The About section now separates the company story, the people and the record of progress so each can be understood quickly.
Why miRoncol exists.
Our purpose, vision, mission and the operating disciplines behind the platform.
Explore the company 02 · LeadershipExperience behind the intelligence.
Meet the leaders connecting company strategy, clinical oncology, diagnostics and bioinformatics.
Meet the team 03 · News and milestonesProgress you can trace.
Follow published research, awards, partnerships, leadership appointments and company progress.
Read the newsDifferent experience. Shared direction.
The platform is being built by leaders whose experience covers science, clinical care, diagnostics, company building and marketing, including how the opportunity is communicated to investors, partners and the public.
Victoria Xu
An entrepreneur and investor with graduate training spanning bioinformatics and public management. Victoria leads miRoncol’s strategy, operations and path from scientific opportunity to preventive-health applications.
Read profile
Christopher M. Gallagher, MD
A practicing medical oncologist with more than 20 years in cancer care and clinical research. Chris guides miRoncol’s clinical strategy, scientific discipline and patient-centred application.
Read profile
Gilles Erb, PhD
Gilles brings more than 20 years in oncology diagnostics and clinical validation, including experience as Global Scientific Director for Integrated Molecular Medicine at Roche (FMI).
Read profile
Hai Hu, PhD
An award-winning bioinformatics scientist and the scientific architect behind miRoncol’s peer-reviewed blood-based microRNA models for multi-cancer early detection.
Read profile
Stephen Lau
A marketing and technology executive with more than 20 years of experience, a background in cancer research and experience through two company exits. Stephen leads miRoncol’s brand, investor narrative and digital go-to-market strategy.
Read profileThe story is already in motion.
Recent milestones show the company advancing through partnerships, recognition and continued engagement with the preventive-health ecosystem.
miRoncol and YEARS partner in Berlin
A preventive-medicine partnership that introduces miRoncol’s microRNA screening approach to clients in Europe.
Read update November 7, 2025Victoria Xu receives City of Ottawa recognition
miRoncol’s CEO and co-founder was named a 2025 Immigrant Entrepreneur Award recipient.
Read update November 10, 2025Ontario Health Study collaboration profiled
A look at the research collaboration supporting continued development of miRoncol’s oncology application.
Read updateSee how the company’s experience connects.
Explore the microRNA intelligence platform, its first published oncology proof point and its direction across four major chronic disease areas.